Physician profile
Constantine Delis
NPI 1003892043
$1,556.41
in general payments reported to CMS, 2019-2025
12 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $12.86 · 2021: $18.74 · 2022: $252 · 2023: $320 · 2024: $317 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742 · Education: $16.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.23 |
| Education | $16.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $337.80 | 2019-2025 | Epogen, Aranesp, Krystexxa |
| Fresenius USA Marketing, INC. | $268.33 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Otsuka America Pharmaceutical, INC. | $248.96 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $238.00 | 2019-2024 | Farxiga |
| Vifor Pharma, INC. | $158.27 | 2022-2023 | Veltassa |
| Mallinckrodt Hospital Products INC. | $151.35 | 2023 | Acthar |
| Shield Therapeutics INC | $51.25 | 2024 | |
| Travere Therapeutics, INC. | $31.91 | 2023 | |
| Horizon Therapeutics Plc | $21.23 | 2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $18.99 | 2023 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $17.46 | 2022 | |
| Akebia Therapeutics INC | $12.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constantine Delis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.